Cargando…
Chronic thromboembolic pulmonary hypertension
Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication of pulmonary embolism and a major cause of chronic PH leading to right heart failure and death. Lung ventilation/perfusion scintigraphy is the screening test of choice; a normal scan rules out CTEPH. In the case of an abnormal p...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351341/ https://www.ncbi.nlm.nih.gov/pubmed/30545969 http://dx.doi.org/10.1183/13993003.01915-2018 |
_version_ | 1783390556954558464 |
---|---|
author | Kim, Nick H. Delcroix, Marion Jais, Xavier Madani, Michael M. Matsubara, Hiromi Mayer, Eckhard Ogo, Takeshi Tapson, Victor F. Ghofrani, Hossein-Ardeschir Jenkins, David P. |
author_facet | Kim, Nick H. Delcroix, Marion Jais, Xavier Madani, Michael M. Matsubara, Hiromi Mayer, Eckhard Ogo, Takeshi Tapson, Victor F. Ghofrani, Hossein-Ardeschir Jenkins, David P. |
author_sort | Kim, Nick H. |
collection | PubMed |
description | Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication of pulmonary embolism and a major cause of chronic PH leading to right heart failure and death. Lung ventilation/perfusion scintigraphy is the screening test of choice; a normal scan rules out CTEPH. In the case of an abnormal perfusion scan, a high-quality pulmonary angiogram is necessary to confirm and define the pulmonary vascular involvement and prior to making a treatment decision. PH is confirmed with right heart catheterisation, which is also necessary for treatment determination. In addition to chronic anticoagulation therapy, each patient with CTEPH should receive treatment assessment starting with evaluation for pulmonary endarterectomy, which is the guideline recommended treatment. For technically inoperable cases, PH-targeted medical therapy is recommended (currently riociguat based on the CHEST studies), and balloon pulmonary angioplasty should be considered at a centre experienced with this challenging but potentially effective and complementary intervention. |
format | Online Article Text |
id | pubmed-6351341 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-63513412019-02-06 Chronic thromboembolic pulmonary hypertension Kim, Nick H. Delcroix, Marion Jais, Xavier Madani, Michael M. Matsubara, Hiromi Mayer, Eckhard Ogo, Takeshi Tapson, Victor F. Ghofrani, Hossein-Ardeschir Jenkins, David P. Eur Respir J Series Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication of pulmonary embolism and a major cause of chronic PH leading to right heart failure and death. Lung ventilation/perfusion scintigraphy is the screening test of choice; a normal scan rules out CTEPH. In the case of an abnormal perfusion scan, a high-quality pulmonary angiogram is necessary to confirm and define the pulmonary vascular involvement and prior to making a treatment decision. PH is confirmed with right heart catheterisation, which is also necessary for treatment determination. In addition to chronic anticoagulation therapy, each patient with CTEPH should receive treatment assessment starting with evaluation for pulmonary endarterectomy, which is the guideline recommended treatment. For technically inoperable cases, PH-targeted medical therapy is recommended (currently riociguat based on the CHEST studies), and balloon pulmonary angioplasty should be considered at a centre experienced with this challenging but potentially effective and complementary intervention. European Respiratory Society 2019-01-24 /pmc/articles/PMC6351341/ /pubmed/30545969 http://dx.doi.org/10.1183/13993003.01915-2018 Text en Copyright ©ERS 2019 http://creativecommons.org/licenses/by-nc/4.0/ This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. |
spellingShingle | Series Kim, Nick H. Delcroix, Marion Jais, Xavier Madani, Michael M. Matsubara, Hiromi Mayer, Eckhard Ogo, Takeshi Tapson, Victor F. Ghofrani, Hossein-Ardeschir Jenkins, David P. Chronic thromboembolic pulmonary hypertension |
title | Chronic thromboembolic pulmonary hypertension |
title_full | Chronic thromboembolic pulmonary hypertension |
title_fullStr | Chronic thromboembolic pulmonary hypertension |
title_full_unstemmed | Chronic thromboembolic pulmonary hypertension |
title_short | Chronic thromboembolic pulmonary hypertension |
title_sort | chronic thromboembolic pulmonary hypertension |
topic | Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351341/ https://www.ncbi.nlm.nih.gov/pubmed/30545969 http://dx.doi.org/10.1183/13993003.01915-2018 |
work_keys_str_mv | AT kimnickh chronicthromboembolicpulmonaryhypertension AT delcroixmarion chronicthromboembolicpulmonaryhypertension AT jaisxavier chronicthromboembolicpulmonaryhypertension AT madanimichaelm chronicthromboembolicpulmonaryhypertension AT matsubarahiromi chronicthromboembolicpulmonaryhypertension AT mayereckhard chronicthromboembolicpulmonaryhypertension AT ogotakeshi chronicthromboembolicpulmonaryhypertension AT tapsonvictorf chronicthromboembolicpulmonaryhypertension AT ghofranihosseinardeschir chronicthromboembolicpulmonaryhypertension AT jenkinsdavidp chronicthromboembolicpulmonaryhypertension |